MLND News and Press, Millendo Therapeutics From 02/24/20

Millendo Therapeutics (NASDAQ: MLND) was featured in a recent Equity Research Report published by ROTH Capital Partners, LLC. The report reads, “Yesterday, MLND appointed a new CMO only ~2 months away from the Phase 2b ZEPHYR data. With $48.3M in cash and $123M market cap, investors hav...

Millendo Therapeutics, Inc. (Nasdaq: MLND), a late-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases, announced today that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at the 9 th Annual SVB Leerink ...

– Company also provides update on timeline for pivotal ZEPHYR study – Millendo Therapeutics, Inc. (Nasdaq: MLND), a late-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases, announced today that Christophe Arbet...

Arcturus Therapeutics (NASDAQ: ARCT ) initiated with Buy rating and $19 (70% upside) price target at Guggenheim. More news on: Arcturus Therapeutics Holdings Inc., BeyondSpring Inc., Millendo Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases with significant unmet needs, today announced the promotion of Thomas Hoover to the newly created position of Chief Commercia...

Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases with significant unmet needs, today announced that Geoff Nichol, M.B., Ch.B., M.B.A., has been appointed to the Board of Dire...

Gainers: Aurinia Pharmaceuticals (NASDAQ: AUPH ) +95% . More news on: Aurinia Pharmaceuticals Inc., Duluth Holdings Inc., Atreca, Inc., Stocks on the move, Read more ...

Millendo Therapeutics (NASDAQ: MLND ) has priced its public offering of 4,166,667 common shares at $6.00 per share, for gross proceeds of $25M. More news on: Millendo Therapeutics, Inc., Healthcare stocks news, Read more ...

Millendo Therapeutics, Inc. (Nasdaq: MLND), a late-stage biopharmaceutical company developing novel treatments primarily for orphan endocrine diseases, today announced the pricing of its underwritten public offering of 4,166,667 shares of its common stock at a public offering price of $6.00 p...

Millendo Therapeutics (NASDAQ: MLND ) is down 18.8% in light postmarket trade after its proposed equity offering is said to amount to $25M in shares. More news on: Millendo Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...